Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Melanoma 11Breast Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Carcinoma, Merkel Cell 2Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

Gemcitabine 358Fluorouracil 94Oxaliplatin 81Capecitabine 74130-nm albumin-bound paclitaxel 71Albumin-Bound Paclitaxel 70Radiotherapy 67Leucovorin 58Irinotecan 49Erlotinib Hydrochloride 47Cisplatin 44Bevacizumab 31pembrolizumab 30Radiosurgery 30Docetaxel 26Taxes 24Nivolumab 24Cetuximab 24Pancreaticoduodenectomy 20Drug Therapy 17folfirinox 16Cyclophosphamide 16Radiation 15Ipilimumab 13Endoscopic Ultrasound-Guided Fine Needle Aspiration 13Surgical Procedures, Operative 12Sorafenib 12Paclitaxel 12Neoadjuvant Therapy 12irinotecan sucrosofate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pancreatic Neoplasms × talimogene laherparepvec × Clear all
NCT03086642 2024-11-22

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Columbia University

Phase 1 Completed
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00402025 2016-04-15

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

BioVex Limited

Phase 1 Completed
17 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡